Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Blood (2016) 127 (20): 2481–2488.

https://doi.org/10.1182/blood-2015-10-673681

Published: 2016

Includes: Supplemental data

Journal Articles

Planning for the future workforce in hematology research

W. Keith Hoots, Janis L. Abkowitz, Barry S. Coller, Donna M. DiMichele

Blood (2015) 125 (18): 2745–2752.

https://doi.org/10.1182/blood-2015-01-617811

Published: 2015

Journal Articles

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation

Veronica H. Flood, Kenneth D. Friedman, Joan Cox Gill, Sandra L. Haberichter, Pamela A. Christopherson, Brian R. Branchford, Raymond G. Hoffmann, Thomas C. Abshire, Amy L. Dunn, Jorge A. Di Paola, W. Keith Hoots, Deborah L. Brown, Cindy Leissinger, Jeanne M. Lusher, Margaret V. Ragni, Amy D. Shapiro, Robert R. Montgomery

Blood (2013) 121 (18): 3742–3744.

https://doi.org/10.1182/blood-2012-12-471672

Published: 2013

Journal Articles

On the value of portfolio diversity in heart, lung, and blood research

Zorina S. Galis, W. Keith Hoots, James P. Kiley, Michael S. Lauer

Blood (2012) 120 (12): 2361–2364.

https://doi.org/10.1182/blood-2012-08-450643

Published: 2012

Journal Articles

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population

Daniel B. Bellissimo, Pamela A. Christopherson, Veronica H. Flood, Joan Cox Gill, Kenneth D. Friedman, Sandra L. Haberichter, Amy D. Shapiro, Thomas C. Abshire, Cindy Leissinger, W. Keith Hoots, Jeanne M. Lusher, Margaret V. Ragni, Robert R. Montgomery

Blood (2012) 119 (9): 2135–2140.

https://doi.org/10.1182/blood-2011-10-384610

Published: 2012

Journal Articles

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor

Veronica H. Flood, Joan Cox Gill, Patricia A. Morateck, Pamela A. Christopherson, Kenneth D. Friedman, Sandra L. Haberichter, Brian R. Branchford, Raymond G. Hoffmann, Thomas C. Abshire, Jorge A. Di Paola, W. Keith Hoots, Cindy Leissinger, Jeanne M. Lusher, Margaret V. Ragni, Amy D. Shapiro, Robert R. Montgomery

Blood (2010) 116 (2): 280–286.

https://doi.org/10.1182/blood-2009-10-249102

Published: 2010

Journal Articles

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Johnny Mahlangu, MD, Tatiana A. Andreeva, MD, Donald Macfarlane, MD, PhD, Mark T. Reding, MD, Christopher Walsh, MD, Bruce Ritchie, MD, Nadia Ewing, MD, Craig M. Kessler, MD, Christine Kempton, MD, Edward Libby, MD, Nadezda Zozulya, MD, Amy D. Shapiro, MD, Jean St-Louis, MD, Indira Warrier, MD, W. Keith Hoots, MD, Ralph A. Gruppo, MD, Josef N. Mueksch, MD, MBA

Blood (2007) 110 (11): 783.

https://doi.org/10.1182/blood.V110.11.783.783

Published: 2007

Journal Articles

Delays in maturation among adolescents with hemophilia and a history of inhibitors

Sharyne M. Donfield, Henry S. Lynn, Alice E. Lail, W. Keith Hoots, Erik Berntorp, Edward D. Gomperts

Blood (2007) 110 (10): 3656–3661.

https://doi.org/10.1182/blood-2007-05-088062

Published: 2007

Includes: Supplemental data

Journal Articles

An actuarial GPS for hemophilic longevity

W. Keith Hoots

Blood (2007) 110 (3): 791–792.

https://doi.org/10.1182/blood-2007-05-087700

Published: 2007

Journal Articles

A “joint” statement on inhibitor-bypassing therapy

W. Keith Hoots

Blood (2007) 109 (2): 395–396.

https://doi.org/10.1182/blood-2006-10-053439

Published: 2007

Journal Articles

Association between a History of Inhibitors and Delays in Skeletal Maturation in Adolescents with Hemophilia.

Sharyne M. Donfield, PhD, Alice Lail, M.P.H., Edward D. Gomperts, M.D., W. Keith Hoots, M.D., Erik Berntorp, M.D., Ph.D., Henry S. Lynn, Ph.D.

Blood (2006) 108 (11): 1022.

https://doi.org/10.1182/blood.V108.11.1022.1022

Published: 2006

Journal Articles

Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds.

Barbara A. Konkle, Liselotte S. Ebbesen, Guenter K.H. Auerswald, Ute Friedrich, Rolf C.R. Ljung, Harold R. Roberts, W. Keith Hoots

Blood (2006) 108 (11): 1028.

https://doi.org/10.1182/blood.V108.11.1028.1028

Published: 2006

Journal Articles

“Selfless” cytokines, fraternal discord, and inhibitors

W. Keith Hoots

Blood (2006) 107 (8): 3024–3025.

https://doi.org/10.1182/blood-2006-02-001925

Published: 2006

Journal Articles

Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency.

Marilyn J. Manco-Johnson, MD, Thomas C. Abshire, MD, Deborah Brown, MD, George R. Buchanan, MD, Alan R. Cohen, MD, Donna DiMichele, MD, W. Keith Hoots, MD, Cindy A. Leissinger, MD, Kevin McRedmond, MD, Diane J. Nugent, MD, Amy D. Shapiro, MD, Gregory A. Thomas, MD, Leonard A. Valentino, MD, Brenda Riske, MBA, MPA

Blood (2005) 106 (11): 3.

https://doi.org/10.1182/blood.V106.11.3.3

Published: 2005

Journal Articles

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Amy D. Shapiro, Jorge Di Paola, Alice Cohen, K. John Pasi, Margaret A. Heisel, Victor S. Blanchette, Thomas C. Abshire, W. Keith Hoots, Jeanne M. Lusher, Claude Negrier, Chantal Rothschild, David A. Roth, for the Recombinant Factor IX Study Group

Blood (2005) 105 (2): 518–525.

https://doi.org/10.1182/blood-2004-06-2283

Published: 2005

Journal Articles

Transjugular Liver Biopsy in Hemophilia Is Safe with a Minimum of Two Doses of Factor.

Margaret V. Ragni, M.D., Kristen Jaworski, B.S.N., Lisa Boggio, M.D., Doreen B. Brettler, M.D., W. Keith Hoots, M.D., Philip Kuriakose, M.D., Cynthia Jean Rutherford, M.D., Albert B. Zajko, M.D.

Blood (2004) 104 (11): 3078.

https://doi.org/10.1182/blood.V104.11.3078.3078

Published: 2004

Journal Articles

To each according to his need

W. Keith Hoots

Blood (2003) 102 (7): 2313–2314.

https://doi.org/10.1182/blood-2003-07-2566

Published: 2003

Journal Articles

Spontaneous remission of granulocyte colony-stimulating factor–associated leukemia in a child with severe congenital neutropenia

Sima Jeha, Ka Wah Chan, Andrew G. Aprikyan, W. Keith Hoots, Steven Culbert, Hallie Zietz, David C. Dale, Maher Albitar

Blood (2000) 96 (10): 3647–3649.

https://doi.org/10.1182/blood.V96.10.3647

Published: 2000

NARROW

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Planning for the future workforce in hematology research

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation

On the value of portfolio diversity in heart, lung, and blood research

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Delays in maturation among adolescents with hemophilia and a history of inhibitors

An actuarial GPS for hemophilic longevity

A “joint” statement on inhibitor-bypassing therapy

Association between a History of Inhibitors and Delays in Skeletal Maturation in Adolescents with Hemophilia.

Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds.

“Selfless” cytokines, fraternal discord, and inhibitors

Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency.

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Transjugular Liver Biopsy in Hemophilia Is Safe with a Minimum of Two Doses of Factor.

To each according to his need

Spontaneous remission of granulocyte colony-stimulating factor–associated leukemia in a child with severe congenital neutropenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only